Showing 4701-4710 of 20472 results for "".
- ESCALON Trial Tests Corneal Endothelial Cell Therapy for Corneal Edemahttps://reachmd.com/news/escalon-trial-tests-corneal-endothelial-cell-therapy-for-corneal-edema/2487097/Key Takeaways Pooled month 12 data showed improvement in central corneal thickness and best-corrected visual acuity after treatment. No serious treatment-emergent adverse events were reported in study eyes, and common ocular events were included in the
- Cardiovascular Risk in Hidradenitis Suppurativahttps://reachmd.com/news/cardiovascular-risk-in-hidradenitis-suppurativa/2487105/Key Takeaways Pooled associations favored higher risks for ischemic or coronary heart disease, composite cardiovascular disease, myocardial infarction, heart failure, venous thromboembolism, and all-cause mortality. Hypertension was the most frequently
- Short-Acting Psychedelic Trial Reports Rapid MDD Symptom Reductionhttps://reachmd.com/news/short-acting-psychedelic-trial-reports-rapid-mdd-symptom-reduction/2487099/Key Takeaways Blinded treatment with intravenous DMT fumarate was associated with greater depressive symptom reduction at 2 weeks, with separation from placebo also reported at 1 week. Response and remission were reported at 1 week, 2 weeks, and explor
- Surgical Outcomes After Neoadjuvant Pembrolizumab in KEYNOTE-522https://reachmd.com/news/surgical-outcomes-after-neoadjuvant-pembrolizumab-in-keynote-522/2487109/Key Takeaways Pathological complete nodal response at surgery was higher with pembrolizumab plus chemotherapy than with placebo plus chemotherapy. Breast-conserving surgery, mastectomy, and the median intervals to surgery and to adjuvant therapy were s
- Scheduled Birth at Term Reduced Pre-Eclampsia in PREVENT-PEhttps://reachmd.com/news/scheduled-birth-at-term-reduced-pre-eclampsia-in-prevent-pe/2487110/Key Takeaways Birth with pre-eclampsia occurred in 3.9% of the intervention group and 5.6% of the usual-care group. The strategy used 36-week risk assessment and offered planned early-term birth when estimated pre-eclampsia risk was at least 1 in 50.</
- Prp Plus Hyaluronic Acid vs Crosslinked Hya in Knee Osteoarthritishttps://reachmd.com/news/prp-plus-hyaluronic-acid-vs-crosslinked-hya-in-knee-osteoarthritis/2487098/Key Takeaways At 6 months, WOMAC pain on walking favored PRP-HA, and investigators described PRP-HA as non-inferior on WOMAC pain responder assessment over 6 months. PASS WOMAC Pain responses favored PRP-HA, while OMERACT-OARSI and WOMAC pain MCII did
- Subcutaneous Guselkumab Meets Week 12 Endpoint In Ulcerative Colitishttps://reachmd.com/news/subcutaneous-guselkumab-meets-week-12-endpoint-in-ulcerative-colitis/2487100/Key Takeaways Subcutaneous guselkumab induction was associated with higher week 12 clinical remission than placebo. Week 24 clinical remission remained higher in both guselkumab groups than in the placebo group. Adverse events were reported at
- Adaptive Mobile Health Lowers Gestational Weight Gain in Cluster Trialhttps://reachmd.com/news/adaptive-mobile-health-lowers-gestational-weight-gain-in-cluster-trial/2487101/Key Takeaways The intervention group had lower weekly and total gestational weight gain than the standard care group. Fewer intervention patients exceeded Institute of Medicine thresholds for weekly and total gestational weight gain, with relative risk
- From SCALE 2026: Microneedling Treatment Reduces Periorbital Wrinkle Severityhttps://reachmd.com/news/microneedling-treatment-reduces-periorbital-wrinkle-severity/2487121/A prospective clinical study presented at the 2026 Music City SCALE Annual Meeting demonstrated significant improvement in periorbital wrinkles following treatment with the SkinStylus SteriLock MicroSystem (Hydrafacial LLC). The study evaluated the safety and effic
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://reachmd.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,